Taking On Challenges And Growing? – Arrowhead Pharmaceuticals Inc. (ARWR)

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Most recently, Yahoo Finance reported about the stock as it publicized that ARWR: Pipeline Reprioritization to Reduce Cash Burn by up to $100 Million This Fiscal Year.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Stocks Info

This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Arrowhead Pharmaceuticals Inc. is $3.78B. A total of 1.46 million shares were traded on the day, compared to an average of 1.63M shares.

Insider Activity

Insider trades can also provide insight into a stock’s future direction. During the recent three months, ARWR has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 3 BUYs and 13 SELLs from insiders. Insiders purchased 162,683 shares during that period but sold 234,221.

In the most recent transaction, Anzalone Christopher Richard sold 57,499 shares of ARWR for 32.35 per share on Jan 31. After the transaction, the Chief Executive Officer now owns 3,715,048 company shares. In a previous transaction on Jan 12, Hamilton James C sold 7,940 shares at 36.89 per share. ARWR shares that Chief Discovery/Trans Medicine owns now total 210,851.

Among the insiders who sold shares, Vakiener Victoria disposed of 4,720 shares on Jan 11 at a per-share price of $38.10. This resulted in the Director holding 32,001 shares of ARWR after the transaction. In another insider transaction, Waddill William D. sold 3,934 shares at $38.07 per share on Jan 11. Company shares held by the Director now total 47,870.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for ARWR in the last 3 months, the mean price target is $55.15 with high estimates of $90.00 and low estimates of $28.00. In terms of 52-week highs and lows, ARWR has a high of $42.48 and a low of $20.67.

As of this writing, ARWR has an earnings estimate of -$0.16 per share for the current quarter. EPS was calculated based on a consensus of 12 estimates, with a high estimate of $3.27 per share and a lower estimate of -$0.95. The company reported an EPS of -$1.02 in the last quarter, which was -70.00% lower than expectations of -$0.6.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. ARWR’s latest balance sheet shows that the firm has $367.79M in Cash & Short Term Investments as of fiscal 2021. There were $25.55M in debt and $146.54M in liabilities at the time. Its Book Value Per Share was $1.49, while its Total Shareholder’s Equity was $408.82M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ARWR is Buy with a score of 4.31.

Most Popular

Related Posts